Enliven Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
Contents
Other Information
Item 5. Other Information.
On October 19, 2023, Rahul Ballal, Ph.D., a director, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 97,420 shares of our common stock. The trading arrangement is/was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until February 16, 2026, or earlier if all transactions under the trading arrangement are completed.
During our last fiscal quarter, no officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.